Corvus Pharmaceuticals (CRVS) Lowered to Strong Sell at ValuEngine

ValuEngine cut shares of Corvus Pharmaceuticals (NASDAQ:CRVS) from a sell rating to a strong sell rating in a research report sent to investors on Friday morning.

Separately, Zacks Investment Research downgraded shares of Corvus Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, January 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The company has a consensus rating of Hold and an average target price of $20.25.

Corvus Pharmaceuticals (CRVS) opened at $8.03 on Friday. The company has a market cap of $168.96, a price-to-earnings ratio of -2.99 and a beta of -2.39. Corvus Pharmaceuticals has a 1 year low of $7.81 and a 1 year high of $22.14.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its earnings results on Thursday, November 2nd. The company reported ($0.62) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.19. equities research analysts anticipate that Corvus Pharmaceuticals will post -2.82 EPS for the current fiscal year.

In other Corvus Pharmaceuticals news, CEO Richard A. Md Miller purchased 10,000 shares of the stock in a transaction dated Monday, November 20th. The shares were bought at an average cost of $10.79 per share, with a total value of $107,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 46.40% of the company’s stock.

Large investors have recently modified their holdings of the company. New York State Common Retirement Fund grew its position in shares of Corvus Pharmaceuticals by 2,269.1% in the second quarter. New York State Common Retirement Fund now owns 9,500 shares of the company’s stock valued at $115,000 after purchasing an additional 9,099 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Corvus Pharmaceuticals in the fourth quarter valued at about $150,000. Alliancebernstein L.P. acquired a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at about $175,000. California State Teachers Retirement System grew its position in shares of Corvus Pharmaceuticals by 121.2% in the second quarter. California State Teachers Retirement System now owns 14,967 shares of the company’s stock valued at $181,000 after purchasing an additional 8,200 shares during the last quarter. Finally, Teachers Advisors LLC grew its position in shares of Corvus Pharmaceuticals by 338.4% in the second quarter. Teachers Advisors LLC now owns 15,568 shares of the company’s stock valued at $188,000 after purchasing an additional 12,017 shares during the last quarter. 81.42% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.com-unik.info/2018/02/05/corvus-pharmaceuticals-crvs-lowered-to-strong-sell-at-valuengine.html.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit